Article
Mutant p53 in cancer therapy—the barrier or the path
3 Dec 2018
Abstract excerpt
Since wild-type p53 is central for maintaining genomic stability and preventing oncogenesis, its coding gene TP53 is highly mutated in ~50% of human cancers, and its activity is almost abrogated in the rest of cancers. Approximately 80% of p53 mutations are single point mutations with several hotspot mutations. Besides loss of function and dominant-negative effect on the wild-type p53 activity, the hotspot p53...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.